{"schema_version":"secwatch.filing_event.v1","accession":"0001490978-24-000088","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.573387+00:00","generated_at":"2026-05-30T01:46:51.791149+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Schrödinger Q3 total revenue $35.3M (-17% YoY); announces $150M upfront Novartis collaboration","bullets":["Software revenue $31.9M (+10% YoY); drug discovery revenue $3.4M (-75% YoY).","Net loss $38.1M vs $62.0M a year ago; non-GAAP net loss $63.7M.","Novartis pays $150M upfront; potential milestones up to $2.3B plus royalties.","2024 guidance: software rev growth 8-13%; drug discovery rev $20-30M; software gross margin slightly below 2023.","Cash & equivalents $398.4M at Sept 30, 2024; received $48M from Lilly buyout of Morphic."],"urls":{"canonical":"https://secwatch.observer/filing/0001490978-24-000088","json":"https://secwatch.observer/filing/0001490978-24-000088.json","markdown":"https://secwatch.observer/filing/0001490978-24-000088.md","text":"https://secwatch.observer/filing/0001490978-24-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000149097824000088/0001490978-24-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000149097824000088/sdgr-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:46:51.791149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}